# PROFUTURE (methylation, fragmentation and protein test for five cancers)

Source: https://onco.cc/trials/profuture-mced/  
OnCo record `profuture-mced` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese case-control study developing a blood test for five common cancers from DNA methylation, DNA fragments and proteins.

## Summary

PROFUTURE (NCT05874648) is an observational study sponsored by Sixth Affiliated Hospital, Sun Yat-sen University with Shanghai Weihe Medical Laboratory Co., Ltd. It collects blood to develop machine-learning models that combine cell-free DNA methylation, fragmentation and proteomics.

The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 25 May 2023), with an estimated 3,830 participants, a planned start in 7 July 2023 and primary completion expected on 30 April 2024.

## Fields

- Kind: Trial
- Last checked: 2026-10-29
- Also known as: PROFUTURE
- Registry id: NCT05874648
- Phase: observational
- Setting: People newly diagnosed with cancer and people without cancer at Sun Yat-sen University's Sixth Affiliated Hospital
- Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University with Shanghai Weihe Medical Laboratory Co., Ltd.
- Enrolled: 3830

## Sources

- ClinicalTrials.gov NCT05874648: https://clinicaltrials.gov/study/NCT05874648

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [cfDNA fragmentomics](https://onco.cc/technologies/fragmentomics/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/profuture-mced.json